BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fox LC, Cohney SJ, Kausman JY, Shortt J, Hughes PD, Wood EM, Isbel NM, de Malmanche T, Durkan A, Hissaria P, Blombery P, Barbour TD. Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand: Thrombotic microangiopathy in Aust/NZ. Nephrology 2018;23:507-17. [DOI: 10.1111/nep.13234] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Poullin P. [Treatment of immune-mediated thrombotic thrombocytopenic purpura: A decisive turning point]. Transfus Clin Biol 2021;28:380-5. [PMID: 34464709 DOI: 10.1016/j.tracli.2021.08.347] [Reference Citation Analysis]
2 Stratford LMI, Nahoor I, Dos Santos K, Dos Santos AA. A case of thrombotic microangiopathy of unknown aetiology, clinically presenting as an acute surgical abdomen. BMJ Case Rep 2019;12:e230553. [PMID: 31780612 DOI: 10.1136/bcr-2019-230553] [Reference Citation Analysis]
3 Lokki AI, Heikkinen-Eloranta J. Pregnancy induced TMA in severe preeclampsia results from complement-mediated thromboinflammation. Hum Immunol 2021;82:371-8. [PMID: 33820656 DOI: 10.1016/j.humimm.2021.03.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Li XM, Mo XY, Huang GQ, Zhang FJ. Therapeutical plasma exchange for thrombotic thrombocytopenic purpura in the emergency department: A single center experience. Am J Emerg Med 2021;46:556-9. [PMID: 33214018 DOI: 10.1016/j.ajem.2020.11.019] [Reference Citation Analysis]
5 Han X, Li C, Zhang S, Hou X, Chen Z, Zhang J, Zhang Y, Sun J, Wang Y. Why thromboembolism occurs in some patients with thrombocytopenia and treatment strategies. Thromb Res 2020;196:500-9. [PMID: 33091704 DOI: 10.1016/j.thromres.2020.10.005] [Reference Citation Analysis]
6 Jayasinghe K, Quinlan C, Stark Z, Patel C, Mallawaarachchi A, Wardrop L, Kerr PG, Trnka P, Mallett AJ; KidGen Collaborative. Renal genetics in Australia: Kidney medicine in the genomic age. Nephrology (Carlton) 2019;24:279-86. [PMID: 30239064 DOI: 10.1111/nep.13494] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
7 Palma LMP, Sridharan M, Sethi S. Complement in Secondary Thrombotic Microangiopathy. Kidney Int Rep 2021;6:11-23. [PMID: 33102952 DOI: 10.1016/j.ekir.2020.10.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
8 Kim MJ, Lee H, Kim YH, Jin SY, Kim HJ, Oh D, Jeon JS. Eculizumab therapy on a patient with co-existent lupus nephritis and C3 mutation-related atypical haemolytic uremic syndrome: a case report. BMC Nephrol 2021;22:86. [PMID: 33691638 DOI: 10.1186/s12882-021-02293-2] [Reference Citation Analysis]
9 Raval JS, Rollins-Raval MA, Mazepa MA, Park YA. Heterogeneity of diagnosis, treatment, and management for immune thrombotic thrombocytopenic purpura: Are we still peering through the looking glass? J Clin Apher 2020;35:236-7. [PMID: 32449953 DOI: 10.1002/jca.21777] [Reference Citation Analysis]